Abstract
Lesion research in humans and non-human primates classically maps the behavioral effects of focal damage to the directly-injured brain region. However, given the interconnectedness of the brain, it has long been known that such damage can also have distant effects. Modern imaging methods provide new ways to assess those effects. Further, triangulating across these methods in a lesion model may shed light on the biological basis of structural and functional networks in the healthy brain. We characterised network organization assessed with multiple MRI imaging modalities in 13 patients with chronic focal damage affecting either superior or inferior frontal gyrus (SFG, IFG) and 18 demographically-matched healthy Controls. We first defined structural and functional network parameters for the two frontal regions-of-interest in healthy Controls, and then used voxel-based morphology (VBM) and tract-based spatial statistics (TBSS) analyses to investigate structural grey matter (GM) and white matter (WM) differences between patients and Controls. The functional and structural networks defined in healthy participants were then used to constrain interpretation of the whole brain network effects in patients. Finally, we applied dual regression to examine the differences in functional coupling to large-scale resting state networks (RSNs), focusing on the RSNs which most overlapped structurally with the lesion sites. Overall, the results show that lesions are associated with widespread within-network GM loss at sites distal from the lesion, yet leave WM and RSNs relatively preserved. Lesions to either prefrontal region had a very similar impact on structural networks, but SFG lesions had larger impact on RSNs than did IFG lesions. The findings provide evidence for causal contributions of specific prefrontal regions to structural and functional brain networks in humans, relevant to interpreting connectomic findings in studies of healthy people or those with psychiatric illnesses.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
The work was supported by the Canadian Institutes of Health Research. The work of R.B.M. is supported by the Biotechnology and Biological Sciences Research Council UK [BB/N019814/1] and the Netherlands Organization for Scientific Research [452-13-015]. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust [203129/Z/16/Z]. M.R.G. has received research funding from the Canadian Institutes of Health Research, National Institutes of Health, Sidney Baer Foundation and Fonds de Recherche en Sante du Quebec (Chercheur-Boursier Award). LKF acknowledges support from McGill Universitys Healthy Brains for Healthy Lives Canada First Research Excellence Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board at McGill University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not available due to ethical restrictions